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Abstract
Background: Patients with chronic kidney disease (CKD) are at a greatly increased risk of developing cardiovascular
disease. Recently developed guidelines address multiple risk factors and life-style interventions. However, in current
practice few patients reach their targets.
A multifactorial approach with the aid of nurse practitioners was effective in achieving treatment goals and reducing
vascular events in patients with diabetes mellitus and in patients with heart failure. We propose that this also holds for
the CKD population.
Design: MASTERPLAN is a multicenter randomized controlled clinical trial designed to evaluate whether a multifactorial
approach with the aid of nurse-practicioners reduces cardiovascular risk in patients with CKD. Approximately 800
patients with a creatinine clearance (estimated by Cockcroft-Gault) between 20 to 70 ml/min, will be included. To all
patients the same set of guidelines will be applied and specific cardioprotective medication will be prescribed. In the
intervention group the nurse practitioner will provide lifestyle advice and actively address treatment goals. Follow-up will
be five years. Primary endpoint is the composite of myocardial infarction, stroke and cardiovascular mortality. Secondary
endpoints are cardiovascular morbidity, overall mortality, decline of renal function, change in markers of vascular damage
and change in quality of life. Enrollment has started in April 2004 and the study is on track with 700 patients included on
October 15th, 2005. This article describes the design of the MASTERPLAN study.
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Background
Patients with chronic kidney disease are at a greatly
increased risk of developing cardiovascular disease
(CVD)[1,2]. This is most prominent in patients on renal
replacement therapy but also firmly established in
patients with mild renal dysfunction[3]. This increased
cardiovascular risk in patients with chronic kidney disease
(CKD) is the resultant of a multitude of risk factors.
Among these risk factors are: all known traditional risk
factors, a number of them evidently more prevalent than
in the general population, risk factors that are associated
with or worsened by renal insufficiency (anaemia, distur-
bances in calcium-phosphorusbalance, oxidative stress,
inflammation) and renal insufficiency itself [4-7].
Several guidelines have been formulated, both nationally
and internationally, to assist physicians in adequately
reducing cardiovascular risk [8-11]. However it is well
known that patients do not reach treatment-goals formu-
lated in these guidelines[12]. This has also been estab-
lished in patients with renal disease[13,14]. In patients
with diabetes mellitus and heart failure a multifactorial
intervention implemented by nurse-practitioners signifi-
cantly improved metabolic control and reduced cardio-
vascular events [15-18].
Given the high cardiovascular risk and the multitude of
modifiable risk factors a multifactorial approach could
very well also be of benefit for patients with CKD. This has
been suggested several times but has never been proven.
[4,19,20] Most risk factors that promote CVD also pro-
mote decline of renal function. Effectively addressing
these risk factors might therefore also delay renal function
decline[21,22].
Design
The MASTERPLAN study is designed as a multicenter ran-
domized controlled clinical trial with a duration of 5 years
of follow-up.
Aims & primary outcome
The MASTERPLAN study aims to show that in patients
with mild to moderate CKD strict implementation of cur-
rent guidelines by a nurse practitioner, with emphasis on
the use of cardioprotective medication and lifestyle
changes, results in a reduction of a composite endpoint of
myocardial infarction, stroke and cardiovascular mortal-
ity.
Cardiovascular morbidity, overall mortality, quality of
life, percentage of patients achieving treatment goals,
changes in renal function and changes in markers of vas-
cular damage will be considered as secondary outcomes.
Measurements
Changes in renal function will be documented by annu-
ally measuring creatinine clearance from a 24-hour urine
sample and measurement of the serum creatinine. Quality
of life will be assessed through questionnaires that will be
filled out by all participants annually. Markers of vascular
damage will be recorded annually in a proportion of the
patients. These markers address different aspects like
endothelial function, arterial compliance and atheroscle-
rosis in various vascular beds. Pulse wave analysis (PWA)
and pulse wave velocity (PWV) will be measured in
approximately 300 patients. Aortic pulse wave forms and
aortic pulse wave velocity are indicators of arterial stiff-
ness. PWV has been shown to be an independent predic-
tor for cardiovascular risk[23,24]. PWA and PWV
measurements have been validated and can be measured
in a reproducible manner[25]. Carotid intima media
thickness (CIMT) evaluation through B-mode sonography
will also be measured in approximately 150 patients.
Increased CIMT is associated with an elevated risk of car-
diovascular disease[24]. Change in CIMT has been shown
to result from risk factor modifications in a variety of pop-
ulations[26]. CIMT measurement has been validated and
shown to be reproducible[27].
Blood pressure will be recorded twice per year using a
non-invasive automated oscillometric device. Patients
will stay in a supine position for 30 minutes, blood pres-
sure will be recorded every three minutes. The last five
measurements will be used for analysis. Conventional
office readings using the auscullatory method will also be
documented.
Recruitment and screening
All subjects will be recruited from the outpatient nephrol-
ogy or internal medicine clinic of nine Dutch hospitals.
Patients are identified by checking their medical records
for compatibility with the inclusion criteria prior to a reg-
ular outpatient visit. Renal function will be estimated
using the Cockcroft-Gault formula (with a correction for
body surface area as of April 15th 2005)(appendix A). The
Cockcroft-Gault equation has been extensively validated
and is generally appreciated as a useful tool to estimate
creatinine clearance[28,29]. The physician will give every
eligible patient a brief verbal explanation and extensive
written information about the study. A week later follow-
up by the nurse practitioner will be performed. Upon ver-
bal consent to participate in the study, the patient will be
invited to the office. In this visit the in- and exclusion cri-
teria will be checked thoroughly, written informed con-
sent will be acquired and subsequently baseline
measurements will be performed. The medical ethics
committees of the participating hospitals have approved
the conduct of the study.Trials 2006, 7:8 http://www.trialsjournal.com/content/7/1/8
Page 3 of 9
(page number not for citation purposes)
Recruitment began in April 2004 and is estimated to con-
tinue until December 2005. About 60% of patients
deemed eligible by their physician and asked to partici-
pate in the study, actually participate and are included.
The main reasons for non-participation appear to be:
reluctance of the patient to changes in drug therapy and
inability of the patient to attend the required visits. On
December15, 2005 793 patients had been included.
In- and exclusion criteria
Patients are eligible for inclusion when they fulfill the fol-
lowing criteria:
• The subject is at least 18 years old
• The subject is diagnosed with CKD with a creatinine
clearance estimated by the Cockcroft-Gault equation
between 20 and 70 ml/min.
• The subject is able and willing to provide written
informed consent
The following conditions are considered exclusion crite-
ria:
• A renal transplant less than a year before inclusion
• Acute renal failure or rapidly progressive glomerulone-
phritis established by the treating physician
• Any malignancy less than five years before inclusion
other than basocellular or squamous cell carcinoma of the
skin.
• Participation in other clinical trials requiring the use of
study medication
From April 15th 2005 until the end of the inclusion the
Cockcroft-Gault equation was modified to take into
account body surface area according to recent insights
into the applicability of formulas to estimate renal func-
tion [30-33]. This modification was approved by the med-
ical ethics committee.
Baseline evaluation and randomization
Table 1 summarizes the data collected at baseline evalua-
tion. After the baseline evaluation, the patient will be ran-
domized to either nurse practitioner care or physician
care. Randomization to treatment is stratified by center
and renal transplant status using a web-based randomiza-
tion module and performed in predefined blocks of cer-
tain numbers of patients.
Table 1: Data collection
Visit Baseline 1 Visit 2 Visit 3 Visit 4 Visit 5
M o n t h 0 369 1 2
Informed Consent x
Demographic data x
Medical history x
In- and exclusion criteria x
Randomization x
Endpoints xxxx
W e i g h t x xxxx
Waist-hip ratio x x
Ankle-Brachial Index x x
RR and HR in sitting position x x x x x
RR 30 minutes Dynamap x x x
Smoking habit x x x x x
Medication use x x x x x
Three monthly Laboratory evaluationa x xxxx
Annual Laboratory evaluation b xx
ECG x x
PWV (Proportion of patients) x x
Carotid-IMT (Proportion of patients) x x
Questionnaires c xx
a: Three monthly Laboratory evaluation: Hematology: Hb, Ht, trombocyte count; Chemistry: sodium, potassium, calcium, phosphate, bicarbonate, 
urea, creatinine, albumin; Urinalysis: spot urine creatinine, albumin, total protein
b: Annual Laboratory evaluation: Hba1c, uric acid, PTH, total-cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides; Urinalysis: 24 hr urine 
sodium, creatinine, albumin, total protein
c: Questionnaires: Quality of Life: SF-36, EQ-5D; Physical activity: SQUASH; Dietary composition; Erectile dysfunctionTrials 2006, 7:8 http://www.trialsjournal.com/content/7/1/8
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Treatment groups
To all patients the same set of guidelines and treatment
goals, represented in Table 2 and Table 3, apply. Both
patients and physicians are provided with information
about the beneficial effects of multifactorial risk factor
management regardless of treatment allocation. In the
intervention group nurse practitioners, supervised by a
qualified nephrologist, will actively pursue lifestyle inter-
vention (physical exercise, nutritional counseling, weight
reduction and smoking cessation), the use of specified
cardioprotective medication and the implementation of
current guidelines. The nurse practitioner will check regu-
larly whether treatment goals have been met and when
deemed appropriate adjust treatment to achieve target val-
ues. Modification of therapy will be executed according to
flowcharts that have been derived from current guidelines.
Physician care comprises 'usual care' conform the guide-
lines mentioned in Table 2. In contrast to the intervention
group and in agreement with real life practice no extra
incentives to adhere to the guidelines will be supplied.
Table 2: Goals and relevant guidelines for cardiovascular risk factors in MASTERPLAN
Risk factors Goal Guideline
Blood pressure </= 130/85 mm Hga NFNb8, KDOQIc[10]
Proteinuria Protein excretion in urine < 0.5 g/day KDOQIc[10]
Lipids KDOQIc[11,44]
Fasting LDL < 2.6 mmol/l
Anemia NFNb[45],
Hemoglobin concentration > 6.8 mmol/l KDOQIc[46]
Glucose NHGd [47]
Fasting glucose < 7.0 mmol/l
Non Fasting glucose < 9.0 mmol/l
Calcium and Phosphate metabolism NFNb[8],
Phosphate </= 1.8 mmol/l KDOQIc[48]
PTH < 18 pMol/l**
Healthy Nutrition GRf[49]
Protein 0.8–1.0 g/kg ideal bodyweight/day
Sodium 2000 mg/day
Fat Reduce fat, unsaturated fats preferred
Energy 30–35 kcal/kg ideal bodyweight/day
Overweight Body mass Index <25 kg/m2
Physical exercise 5×/week 30 minutes moderate exercise NNGBg[50]
Smoking To Quit NFNb[8]
a In case of proteinuria > 1 g/day: 125/75 mm Hg
b NFN: Nederlandse Federatie voor Nefrologie (Dutch Federation for Nephrology)
c KDOQI: Kidney Disease Outcomes Quality Initiative
d NHG: Nederlands huisartsen genootschap (Dutch College of General Practitioners)
e smaller than three times the upper limit of the normal range f GR: Gezondheidsraad (Health Council of the Netherlands)
g NNGB: Nederlandse Norm voor Gezond Bewegen (Dutch Standard of Healthful Physical Activity)
Table 3: Standard medication to reduce cardiovascular risk in MASTERPLAN
Medication Recommended dose Point of impact
HMG-CoA Reductase Inhibitor (statin) e.g. atorvastatin 10 mg daily (or comparable 
dose of other statin)
Lipid-metabolism
Acetylsalicylic acid 80 mg daily Thrombocyte aggregation
Folic Acid 5 mg daily Homocysteine metabolism
ACE inhibitor or Angiotensin Receptor Blocker 
(ARB)
e.g. enalapril 5 mg twice daily (or comparable 
dose of other ACE inhibitor) or irbesartan 75–
150 mg (or comparable dose of other ARB) 
daily
Blood pressure, renal function and cardiac pre- 
and afterload
a In case of proteinuria > 1 g/day: 125/75 mm Hg b NFN: Nederlandse Federatie voor Nefrologie (Dutch Federation for Nephrology) c KDOQI: 
Kidney Disease Outcomes Quality Initiative d NHG: Nederlands huisartsen genootschap (Dutch College of General Practitioners) e smaller than 
three times the upper limit of the normal range f GR: Gezondheidsraad (Health Council of the Netherlands) g NNGB: Nederlandse Norm voor 
Gezond Bewegen (Dutch Standard of Healthful Physical Activity)Trials 2006, 7:8 http://www.trialsjournal.com/content/7/1/8
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Clinical data
The intervention group will receive follow up by the nurse
practitioner as often as is indicated by the guidelines and
the sort of lifestyle intervention the patient receives. Addi-
tional data will be collected for trial purposes quarterly as
described in table 1. The physician care group will receive
an automated non-invasive blood pressure measurement
two times a year. Annually each patient will be invited in
the office to undergo a series of measurements and to fill
out questionnaires. At the other time-points (represented
in Table 1) present clinical data derived from the medical
records will be recorded in the case report form.
The patients will fill out several questionnaires. Firstly
quality of life will be assessed using the SF-36 (Dutch ver-
sion) and EQ-5 D (Dutch version) questionnaires[34,35].
Secondly the Short Questionnaire to asses health enhanc-
ing physical activity will be given to subjects[36]. Thirdly
a Food questionnaire developed by the Wageningen Uni-
versity will deliver information about the composition of
the diet of the subjects[37].
Data management
The entire study is performed according to the ICH-GCP
guidelines, including on-site monitoring. The data will be
documented in a case report form, via a validated web-
based structure. Investigators will fill out the required data
of a visit in an Internet application based on PDF files.
Upon completing the form they will start the submission
process. Before submission the data are verified and
passed through an editing process to check for logical
inconsistencies within the data. Any discrepancies need to
be corrected before actual submission can take place. The
data will be sent to a web server located in the data man-
agement center. The data are immediately transferred into
a SQL server database.
The questionnaires are all in Teleform format and mailed
to the data management center. Filled out questionnaires
are scanned and data are immediately transferred to the
same database used to store the clinical data. A specified
validation procedure has been developed to check incon-
sistencies and to generate and process queries.
Endpoint collection and evaluation
The primary endpoint has been defined as follows, based
on experience in other studies run at the UMCU [38,39].
• Myocardial infarction is defined as evident new ischemic
changes on an ECG or an established rise and fall pattern
of cardiac enzymes.
• Stroke is defined as characteristic clinical symptoms of
stroke accompanied by signs of recent ischemia using an
appropriate imaging technique (CT-scan or MRI).
• Cardiovascular mortality is defined as death due to myo-
cardial infarction, stroke, ruptured abdominal aneurysm,
and terminal heart failure. Also sudden death will be
regarded as part of cardiovascular mortality.
All suspected events, which might contribute to the pri-
mary endpoint, will be evaluated by an independent end-
point-committee. The committee will evaluate these
events using definitions for the different events which are
also used in other Dutch trials [38,39].
Secondary endpoints are collected via clinical data, ques-
tionnaires or specified procedures. The SphygmoCor sys-
tem (pulse wave velocity system and blood pressure
analysis system, PWV Inc., Sydney Australia) is used to
assess PWV and to analyze the arterial pulse contours.
Pulse contours will be obtained by applanation tonome-
try at the carotid, radial and femoral arteries. Independent
investigators blinded for treatment allocation of the sub-
ject will perform evaluation of recorded data. CIMT
assessment will be performed using B-mode ultrasonogra-
phy of both carotid arteries with a 7,5-MHz linear array
transducer to assess the presence of plaques in the com-
mon carotid artery, bifurcation and internal carotid artery.
All measurements will be recorded on video and evalu-
ated off-line by independent evaluators blinded for treat-
ment allocation of the patient [40].
Nurse practitioners
The nurse practitioners are all qualified nurses with sev-
eral years of experience and affinity for nephrology. They
received extensive education in cardiovascular risk reduc-
tion with emphasis on current guidelines, they were famil-
iarized with the contents of the flowcharts and all were
uniformly trained in interview techniques to support
them in implementing lifestyle-modification and maxi-
mizing compliance. Completion of the official Dutch
Nurse Practitioner training program was no prerequisite
to function as a nurse practitioner in this study.
Statistical and data analysis
Power analysis
To detect a 50% between-group difference in the trial pri-
mary endpoint with a pre-estimated 5-year event inci-
dence of 13.5% for the control group [16,41], a power of
80% and a two-sided type I error α of 5%, at least 640
patients will have to be included. Taking into account a
possible loss to follow-up of 15%, at least 740 patients
will be randomized.
Group sequential analysis
Group sequential analysis will be used to evaluate the pri-
mary endpoints and to monitor the safety data. Sequential
analysis is a statistical approach where one conducts sig-
nificance tests over time as the data are collected. Sequen-Trials 2006, 7:8 http://www.trialsjournal.com/content/7/1/8
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tial analysis and its application in clinical trials has been
described extensively by Whitehead [42]. The general
approach is as follows. A null hypothesis H0 and an alter-
native hypothesis H1 are formulated for a suitable meas-
ure θ of treatment difference. For this study with a survival
type outcome variable, θ is equal to the logarithm of the
hazard ratio (HR). H0 is formulated as "no difference in
the occurrence of the primary endpoints between the two
trial arms" or θ = 0 (i.e. HR = 1). The alternative hypothe-
sis H1 is formulated as |θ | ≥ log(0.48) = 0.73 group. Two
test statistics, Z and V, can be derived depending on the
type of response variable. Z is a measure of the treatment
difference; for survival data Z is the observed number of
events in the control group minus the expected number of
events given treatment equivalence (i.e. the number of
events that would have occurred if the same proportion of
events was found in the intervention group and in the
control group).V reflects the amount of information
about θ contained in Z; for survival data V is approxi-
mately equal to a quarter of the number of events
observed. The sequential analysis requires critical bound-
aries to be specified in advance. These boundaries depend
onθ, the type I error α and the power 1-β. For each new
group of patients, values of Z and V are calculated and pre-
sented graphically by plotting Z against V (see Figure1 for
an illustration of a double-sided sequential test). Based on
the path of cumulative (Z, V)-points, one of the following
three decisions is made:
1) the upper or the lower (continuous) boundary is
crossed: stop the data collection and reject the null
hypothesis;
2) one of the inner wedge-shaped (dashed) boundaries is
crossed: stop the data collection and accept the null
hypothesis;
3) continue the data collection: the cumulative data are
inadequate to draw a conclusion yet.
With a sequential approach a trial can be stopped earlier,
on average, than with a fixed sample size approach. Using
a sequential design between 460 and 716 patients would
have to be included. (The number of patients to be
included can not be fixed beforehand because patient data
are analyzed cumulatively and a decision is made to stop
or to continue the trial according to the interim results.)
Due to the large difference between the duration of the
inclusion period and that of the follow-up, it will not be
possible to implement this potential benefit in the design
of the trial. Although the length of follow-up in this trial
in relation to the period scheduled for inclusion does not
allow for a reduction in sample size other benefits of
group sequential analysis remain present. Earlier clarity
on the primary endpoint could allow for earlier stopping
of the trial and thus result in saving time and funds for
other experiments. Also safety related issues, which are to
be monitored one-sided, will possibly be identified earlier
and in this way patient safety is guaranteed throughout
the trial.
Statistical methods
Group sequential (or interim) analyses will be performed
using the double triangular test as described by White-
head [42] and implemented in the computer program
PEST version 4 [43]. The analyses will be performed by an
independent data safety monitoring board (DSMB) con-
sisting of a nephrologist, an internist and a statistician.
They meet every 6 months to monitor various aspects of
the study, including recruitment, adverse events and
interim analyses of the primary endpoints.
The results of the study will be analyzed following the
'intention to treat' principle. This means that subjects will
be analyzed according to the group they have been allo-
cated to by the randomization. Results will be presented
as Kaplan-Meier curves for the two treatments and the dif-
ference between the treatments will be analyzed using a
log-rank test. For the primary outcome variables the log-
rank test will be adjusted for the effect of the cumulative
data analyses. Results will be presented for all cause mor-
tality and CV events separately.
The primary analysis of CIMT progression wiw ll be per-
formed using a linear random coefficient (Laird-Ware)
model using real visit days, treatment and clinical center
as independent variables. For each participant, the inter-
cept and slope of CIMT change over time is assumed to be
a normally distributed random variable with different
means for the two treatment groups. The mean slope for
the nurse practitioner group will be compared to that for
nephrologist-care group using linear contrasts and a 5%
significance level. Additional exploratory analyses will
evaluate the impact of including baseline IMT, lumen
diameter, ultrasound reader, and center as additional co-
variates.
The data analytic approach to arrive at the PWV outcome
variable is similar to that of the CIMT outcome. Adjust-
ments that will be taken into account in the estimates are
changes in MAP and changes in heart rate, since both are
closely related to PWV.
Discussion
Limitations of the study
There are several limitations to the study mostly due to
unavoidable decisions.
1. Although many patients receiving standard care are not
treated according to current guidelines it is ethically notTrials 2006, 7:8 http://www.trialsjournal.com/content/7/1/8
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possible to withhold information and advice on these
guidelines from the control group. Therefore all patients
receive information about risk factor management and all
physicians are informed about the treatment goals. This
may result in improved treatment in the control group
thereby attenuating the potential difference in cardiovas-
cular events between the two treatment arms.
2. Due to the sort of intervention blinding is not possible
for patients or physicians. This is unavoidable since some
physicians will be treating or supervising both physician
care and nurse practitioner care patients. Again, attenua-
tion of group differences may occur.
3. The multifactorial intervention will make it impossible
to single out one aspect of the intervention as being the
most beneficial. Since trials establishing the exact amount
of risk reduction per risk factor intervention are missing in
patients with mild to moderate renal dysfunction, such
information would have been most useful. As pointed out
earlier however the choice for a multifactorial design has
received ample consideration. As a consequence of this
choice for a multifactorial approach sample size is too
small to allow for a definite statement about a single risk
factor. A study large enough to establish the benefits of
one aspect of the intervention would require thousands of
patients and the logistics and funding necessary to realize
this are not present for investigator driven research.
Conclusion
Cardiovascular risk in patients with CKD is very high,
multifactorial in origin and present early in the course of
CKD. Effectively addressing risk factors will reduce cardi-
ovascular risk significantly. A multifactorial approach
with the aid of nurse practitioners has been shown to be
effective in other high-risk populations. The MASTERP-
LAN trial is designed to establish the effects of such a mul-
tifactorial approach in patients with mild to moderate
renal insufficiency. The MASTERPLAN trial is a unique
multicenter randomized clinical trial because it investi-
gates the effects of a multifactorial approach to reduce car-
diovascular events in a population until now rarely
targeted despite a huge cardiovascular risk. The employ-
ment of the nurse practitioner provides a valuable means
of implementing the multifactorial intervention.
Appendix A
The Cockcroft-Gault equation
The Cockcroft-Gault equation modified to correct for
body surface area (effective from april 15th 2005).
Body Surface Area will be estimated using the formule by
Dubois and Dubois.
Appendix B
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• Radboud University Nijmegen Medical Center,
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